Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases

NIH RePORTER · NIH · N01 · $11,270,810 · view on reporter.nih.gov ↗

Abstract

To support the advanced development of candidate therapeutics for biodefense pathogens or emerging infectious diseases. The supported research and development activities will progress the therapeutic product development and may include lead optimization, candidate selection, preclinical and IND enabling studies, Chemistry, Manufacturing, and Controls (CMC), IND submission, clinical safety and efficacy assessment.

Key facts

NIH application ID
11047618
Project number
75N93022C00061-P00002-9999-1
Recipient
REVAGENIX, INC.
Principal Investigator
RYAN CIRZ
Activity code
N01
Funding institute
NIH
Fiscal year
2024
Award amount
$11,270,810
Award type
Project period
2022-09-22 → 2025-08-31